Patients’ baseline characteristics at diagnosis
| . | Non-emi group (n = 12) . | Emi group (n = 7) . | P value . |
|---|---|---|---|
| Age at diagnosis, median (range), y | 81 (58-89) | 76 (60-87) | .350 |
| Sex, n (%) | |||
| Female | 6 (50) | 4 (57) | 1.00 |
| Male | 6 (50) | 3 (43) | |
| Baseline laboratories | |||
| APTT, median (range), s | 82.3 (51.1-128) | 84.8 (44.6-96.1) | .967 |
| FVIII:C, median (range), % | 1.0 (<1-7.0) | 1.0 (<1-10) | .370 |
| FVIII inhibitor, median (range), BU/mL | 43.75 (2.1-11 500) | 622 (1.0-4085) | .261 |
| Hb, median (range), g/dL | 7.45 (6.1-9.4) | 8.4 (5.1-16.9) | .374 |
| Underlying conditions | |||
| Autoimmune diseases, n (%) | 0 (0) | 1 (14) | 1.00 |
| Malignant disease, n (%) | 2 (17) | 0 (0) | 1.00 |
| Comorbidities | |||
| Lifestyle-related diseases, n (%) | 10 (83) | 4 (57) | .305 |
| Hypertension, n (%) | 8 (67) | 2 (29) | .170 |
| Diabetes mellitus, n (%) | 5 (42) | 2 (29) | .656 |
| Dyslipidemia, n (%) | 4 (33) | 2 (29) | 1.00 |
| Vascular diseases, n (%) | 8 (67) | 3 (43) | .377 |
| Lung diseases, n (%) | 4 (33) | 0 (0) | .245 |
| Bleeding severity at diagnosis | |||
| Severe | 11 (92) | 3 (43) | .038 |
| Nonsevere | 1 (8) | 4 (57) | |
| Time from first bleeding to diagnosis, median (range), d | 13 (2-162) | 43 (7-185) | <.001 |
| Initial bleeding location | |||
| Subcutaneous hemorrhage, n (%) | 7 (58) | 4 (57) | |
| Intramuscular hemorrhage, n (%) | 6 (50) | 3 (43) | |
| Oral hemorrhage, n (%) | 2 (17) | 0 (0) | |
| Gastrointestinal bleeding, n (%) | 1 (8) | 1 (14) | |
| Epistaxis, n (%) | 1 (8) | 0 (0) | |
| Renal hematoma, n (%) | 1 (8) | 0 (0) | |
| Hematuria, n (%) | 0 (0) | 1 (14) | |
| Hemorrhagic ascites, n (%) | 0 (0) | 1 (14) |
| . | Non-emi group (n = 12) . | Emi group (n = 7) . | P value . |
|---|---|---|---|
| Age at diagnosis, median (range), y | 81 (58-89) | 76 (60-87) | .350 |
| Sex, n (%) | |||
| Female | 6 (50) | 4 (57) | 1.00 |
| Male | 6 (50) | 3 (43) | |
| Baseline laboratories | |||
| APTT, median (range), s | 82.3 (51.1-128) | 84.8 (44.6-96.1) | .967 |
| FVIII:C, median (range), % | 1.0 (<1-7.0) | 1.0 (<1-10) | .370 |
| FVIII inhibitor, median (range), BU/mL | 43.75 (2.1-11 500) | 622 (1.0-4085) | .261 |
| Hb, median (range), g/dL | 7.45 (6.1-9.4) | 8.4 (5.1-16.9) | .374 |
| Underlying conditions | |||
| Autoimmune diseases, n (%) | 0 (0) | 1 (14) | 1.00 |
| Malignant disease, n (%) | 2 (17) | 0 (0) | 1.00 |
| Comorbidities | |||
| Lifestyle-related diseases, n (%) | 10 (83) | 4 (57) | .305 |
| Hypertension, n (%) | 8 (67) | 2 (29) | .170 |
| Diabetes mellitus, n (%) | 5 (42) | 2 (29) | .656 |
| Dyslipidemia, n (%) | 4 (33) | 2 (29) | 1.00 |
| Vascular diseases, n (%) | 8 (67) | 3 (43) | .377 |
| Lung diseases, n (%) | 4 (33) | 0 (0) | .245 |
| Bleeding severity at diagnosis | |||
| Severe | 11 (92) | 3 (43) | .038 |
| Nonsevere | 1 (8) | 4 (57) | |
| Time from first bleeding to diagnosis, median (range), d | 13 (2-162) | 43 (7-185) | <.001 |
| Initial bleeding location | |||
| Subcutaneous hemorrhage, n (%) | 7 (58) | 4 (57) | |
| Intramuscular hemorrhage, n (%) | 6 (50) | 3 (43) | |
| Oral hemorrhage, n (%) | 2 (17) | 0 (0) | |
| Gastrointestinal bleeding, n (%) | 1 (8) | 1 (14) | |
| Epistaxis, n (%) | 1 (8) | 0 (0) | |
| Renal hematoma, n (%) | 1 (8) | 0 (0) | |
| Hematuria, n (%) | 0 (0) | 1 (14) | |
| Hemorrhagic ascites, n (%) | 0 (0) | 1 (14) |
Hb, hemoglobin.
Boldface type for P values indicates statistical significance.